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Introduction
Mesenchymal progenitor cells (MPCs) are multipotent 
cells, derived from various adult tissues, that are capable of 
differentiating into several mesenchymal lineages, 
including osteoblasts, chondroblasts, and adipocytes. A 
large body of data suggested MPCs as a promising 
candidate cell type applicable for repair and regeneration 
of a variety of mesenchymal tissues such as bone, carti lage, 
and muscle [1,2]. MPCs were initially identified and 
isolated from bone marrow (BM) and are characterized by 
the expression of a number of cell surface markers [3‑5]. 
Based on their clonogenic and multipotent differen tiation 
activities, to date, MPCs have been isolated from a number 
of adult tissues, including trabecular bone [6], fat [7,8], 
synovium [9,10], skin [11], thymus [11,12], periodontal 
ligament [13], as well as prenatal and perinatal sources 
such as umbilical cord blood [14], umbilical cord [15], 
palatine tonsil [16], and placenta [17]. The diversity of 
sources facilitates MPC accessibility, but also raises 
questions about possible phenotypic and functional 
discrepancies that must be addressed for their clinical use.
The transforming growth factor‑β (TGF‑β) superfamily 
of secreted factors includes TGF‑β, activins, Nodal, and 
bone morphogenetic proteins (BMPs). The activation of 
the TGF‑β/activin/Nodal signaling pathway through 
SMAD2/3 is associated with the pluripotency of human 
embryonic stem cells (hESCs) and is required for the 
maintenance of their undifferentiated state [18]. Through 
the induction of Oct4, Nanog, Nodal, Wnt3, basic 
fibroblast growth factor (FGF‑2), and FGF‑8, Activin A 
was shown to be a key regulator for the “stemness” main‑
tenance of hESCs [19]. Activin A, like other members of 
the TGF‑β superfamily, has also been described to affect 
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embryogenesis, hematopoiesis, and angiogenesis [20‑22]. 
The actions of activin A are determined by a balance of 
the levels of activin A and its inhibitor, follistatin (FS). FS 
is a natural antagonist that binds activin with high affinity 
and neutralizes its biologic activities by preventing 
activin interaction with its membrane receptors [23,24]. 
Activin ligands exist in three forms: homodimers of the 
βA and βB protein subunits constitute activin A and 
activin B, respectively, and a heterodimer of βA and βB 
protein subunits represents activin AB. These ligands 
signal by binding to specific serine/threonine kinase type II 
(ActRIIA and ActRIIB) receptors. In the adult, activin βA 
subunit mRNA is produced in BM [25] and, like TGF‑β 
[26] and BMPs, activin A is abundantly localized in bone 
matrix [27,28]. BM‑derived stromal fibroblasts were 
reported to be the major source of activin A and FS in the 
BM [29]. The role of activin A in bone metabolism has 
been evaluated in several studies. Although an inhibitory 
effect of activin A on osteoblastic differentiation in rat 
and murine osteoblasts was described [30,31], activin A 
was also shown to stimulate osteoblastogenesis in murine 
bone marrow cultures and, in vivo, promotes bone 
formation and fracture healing in rodents [27‑29,32]. 
Interestingly, it was recently shown that the osteoblastic 
differentiation of MPCs induced by BMP‑2 involved an 
activin‑dominant microenvironment, whereas adipogenic 
differentiation of MPCs in the presence of dexa metha sone 
occurred in an FS‑dominant microenvironment [33]. In 
this study, the authors suggested that activin A inhibits 
adipogenesis by affecting the adipocyte trans crip tional 
factor in favor of osteoblastic differentiation [33,34]. 
Activin βA also was detected in developing carti lage and 
identified as another member of the TGF‑β superfamily 
involved in the induction of limb chondro genesis [35,36]. 
Therefore, activin A is likely to have pleiotropic functions, 
including an essential role in sustain ing hESC pluri‑
potency, and to play a critical role during skeletogenesis.
In addition to the MPCs derived from BM, MPCs that 
show multidifferentiation potential have also been 
isolated from various tissues. However, compared with 
BM‑MPCs, these MPCs of different tissue origins may 
have different cellular properties and therefore present 
differ ential clinical applicability for regenerative medicine. 
It is, therefore, desirable to identify a factor that 
differentially correlates with and provides a functional 
characterization of the individual “stem cell” state of the 
MPCs from various sources. In this regard, activin A, 
which has been shown to play a role in regulating MPC 
properties, may be considered as a candidate factor and 
should be examined for its expression and functional 
correlation with the activities of various MPCs. For this 
purpose, we have undertaken a comparative study of 
MPCs derived from four different tissue sources, 
including BM, palatine tonsil (T), dental pulp (DP), and 
skeletal muscle (M). In line with the current state of 
knowledge of the biology of BM‑derived MPCs, we 
carried out direct comparisons of the phenotypic and 
functional properties of MPCs isolated from these 
different sources. Specifically, we tested the hypothesis 
that activin A may function as a critical regulatory factor 
for MPCs multipotency. We further dissected the require‑
ment of activin A in human MPCs induction toward 
differentiation into chondrocytes, osteoblasts, and adipo‑
cytes. Our findings showed that activin A expression level 
in MPCs discriminates MPCs from different sources in 
terms of proliferation capacity and differentiation poten‑
tial. In addition to a possible role in MPC identity, activin 
A also appears to play a pivotal role in the early stages of 
MPC chondrogenesis and osteogenesis while inhibiting 
adipogenesis. Furthermore, our results show that among 
the four tissue sources compared, BM‑derived MPCs have 
the highest differen tiation potency and represent the most 
desirable cell type for regenerative medicine.
Materials and methods
MPC isolation and culture
Tonsil-derived MPCs (T-MPCs)
With Institutional Review Board (IRB) approval (George 
Washington University, Washington, DC), tonsils were 
obtained after informed consent from patients under‑
going tonsillectomy as a result of recurrent episodes of 
acute tonsillitis. The tissue was minced, digested, and 
processed by direct plating, as described previously [16]. 
Expansion medium consisting of Dulbecco’s modified 
Eagle’s medium (DMEM) (Invitrogen Corporation, Carls‑
bad, CA, USA) with 10% fetal bovine serum (FBS) from 
selected lots (HyClone) and antibiotics (50 µg/ml 
streptomycin and 50 IU/ml penicillin; Invitrogen).
Bone marrow-derived MPCs (BM-MPCs)
Bone marrow (BM) was obtained after informed consent 
from patients (39 to 58 years old) undergoing lower 
extremity reconstructive surgery with IRB approval 
(University of Washington, Seattle, WA, and George 
Washington University) and was processed by direct 
plating, as described previously [37]. BM aspirates were 
plated overnight in T‑150 cm2 culture flasks in the same 
expansion medium as T‑MPCs, and adherent cells were 
obtained similarly. Both T‑MPCs and BM‑MPCs were 
culture‑expanded in expansion medium at 37°C and 5% 
CO2 by using T‑150 Triple Flasks (Nunc), and medium 
changes were done twice weekly.
Traumatized muscle-derived MPCs (M-MPCs)
Traumatically injured muscle was collected with IRB 
approval from the Walter Reed Army Medical Center 
(WRAMC, Washington, DC). Patients considered for 
inclusion in this study had been exposed to orthopedic 
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trauma and sustained extensive soft tissue extremity 
wounds, and informed consent was obtained from each 
patient before tissue collection. These patients arrived at 
WRAMC approximately 3‑7 days after injury, and tissue 
was collected during debridement and irrigation proce‑
dures. The tissue was dissected, minced, digested, and 
plated as described previously [38,39]. The adherent cells 
were cultured in the same expansion medium as 
T‑MPCs. For the first 3 days, the cells were washed with 
Hank’s Balanced Salt Solution (HBSS), and the medium 
was replaced. The cells were subcultured into new flasks 
after tightly packed colony‑forming units (CFUs) were 
observed, and the cells were cultured in basal expansion 
or Growth Medium (GM: DMEM supplemented with 
10% FBS and 1 unit/ml of antibiotics) from that point 
forward. Subsequent subcultures were performed when 
the cells were approximately 85% confluent.
Dental pulp-derived MPCs (DP-MPCs)
Tooth sample collection and the growth of pulp cells 
followed protocols described previously [40,41]. Extrac‑
tion of third molars from healthy patients (aged 16–
26 years) in the Department of Oral Surgery conformed 
to a protocol (H‑29892) approved by the University of 
Maryland Medical School IRB. Pulp‑cell cultures were 
established through enzyme digestion. Minced pulp 
tissues were digested in a solution of 3 mg/ml collagenase 
type I and 4 mg/ml dispase (Sigma) for 30–60 min at 
37°C. Cell suspensions were obtained by passing the 
digested tissues through a 70‑μm cell strainer (Becton‑
Dickinson). Single‑cell suspensions (1 × 105 cells/flask) 
were seeded in 5 × 10‑cm culture flasks containing 
Eagle’s minimum essential medium alpha modification 
(α‑MEM) supplemented with 20% FBS, 2 mmol/L l‑gluta‑
mine, 100 μmol/L l‑ascorbic acid‑2‑phosphate, 100 U/ml 
penicillin‑G, 100 μg/ml streptomycin, and 0.25 μg/ml 
fungizone (Gemini Bio‑Products) and maintained under 
5% CO2 at 37°C. Clonogenic cells were grown to 70% 
confluence, passaged at a 1:3 ratio, and cultured in the 
same expansion medium as T‑MPCs.
Cell-proliferation assay
Cell‑proliferation assays were performed by using the 
Cell Counting Kit‑8 (Dojindo, Kumamoto, Japan). Cells 
were plated in 96‑well plates at 1 × 104 cells per well and 
cultured in the basal growth medium. At the indicated 
time points, cell numbers in triplicate wells were measured 
spectrophotometrically as A450 values of reduced WST‑8 
(2‑(2‑methoxy‑4‑nitrophenyl)‑3‑(4‑nitro phenyl)‑5‑(2,4 
disulfophenyl)‑2H‑tetrazolium, monosodium salt).
Flow cytometry
For flow cytometry, BM‑MPCs, T‑MPCs, DP‑MPCs, and 
M‑MPCs (>2 × 105 cells) were washed and resuspended 
in phosphate‑buffered saline (PBS) + 0.1% FBS (PF), con‑
tain ing saturating concentrations (1:100 dilution) of the 
following conjugated mouse IgG1,κ anti‑human mono‑
clonal antibodies (BD Biosciences): CD14‑PE, CD34‑PE, 
CD45‑FITC, CD73‑PE, CD90‑FITC, CD105‑PE for 1 h at 
4oC. Cell suspensions were washed twice and resus pen‑
ded in PF for analysis on a flow cytometer (FACSCalibur, 
BD Biosciences) by using the CellQuest ProTM software 
(BD Biosciences).
In vitro differentiation
MPCs were induced to undergo adipogenic, osteogenic, 
and chondrogenic differentiation, as described previously 
[37]. For adipogenic differentiation, cells were seeded 
into six‑well tissue‑culture plates at a density of 
20,000 cells/cm2 and treated for 3 weeks with adipogenic 
medium, consisting of DMEM with 10% FBS, and 
supplemented with 0.5 mmol/L 3‑isobutyl‑1‑methyl‑
xanthine (IBMX), 1 μg/ml insulin, and 1 μmol/L dexa‑
metha sone (all from Sigma). For osteogenic differen‑
tiation, cells were seeded into six‑well plates (Corning) 
at a density of 20,000 cells/cm2, and treated for 3 weeks 
with osteogenic medium, consisting of DMEM with 
10% FBS, and supplemented with 10 mmol/L β‑glycerol‑
phosphate, 10 nmol/L dexamethasone, 50 μg/ml 
ascorbic acid‑2‑phosphate, and 10 nmol/L 1,25 di‑
hydroxy vitamin D3 (Biomol International L.P., Plymouth 
Meeting, PA). To induce chondrogenic differentiation, 
96‑microwell poly propylene plates (Nunc, Roskilde, 
Denmark) were seeded with 300,000 cells per well, and 
cell pellets formed by centrifugation at 1,100 rpm for 6 
minutes. The pellet cultures were treated for 3 weeks 
with chondrogenic medium, consisting of high‑glucose 
DMEM supple men ted with 100 nmol/L dexamethasone, 
50 μg/ml ascorbic acid‑2‑phosphate, 100 μg/ml sodium 
pyruvate, 40 μg/ml l‑proline, 10 ng/ml recombinant 
human transforming growth factor‑β3 (TGF‑β3; R&D 
Systems, Minneapolis, MN), and 50 mg/ml ITS‑premix 
stock (BD Biosciences).
Histochemistry
Oil Red O Staining
Three‑week adipogenic cultures of MPCs were rinsed 
twice with PBS, fixed in 4% buffered paraformaldehyde, 
stained with Oil red O (Sigma) for 5 minutes at room 
temperature, and counterstained with Harris‑Hematoxy‑
lin Solution (Sigma), to visualize lipid droplets.
Alkaline phosphatase and alizarin red S staining
MPCs cultured for 3 weeks in osteogenic medium were 
fixed in 4% paraformaldehyde, rinsed, and stained for 
alkaline phosphatase with Naphthol AS‑BI substrate 
(Sigma) for 30 minutes at 37ºC in the dark. Osteogenic 
cultures were also fixed with 60% isopropyl alcohol and 
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stained for 3 minutes with 2% (wt/vol) Alizarin Red S 
(Rowley) at pH 4.2 to detect mineralization.
Alcian blue and picrosirius red staining
Chondrogenic cell pellets were fixed in 4% buffered 
paraformaldehyde, rinsed with PBS, serially dehydrated, 
paraffin embedded, and sectioned at 10‑μm thickness. 
Sections were stained with Alcian blue (pH 1.0) to detect 
sulfated proteoglycans and with Picrosirius Red (0.1% wt/
vol in saturated picric acid) to visualize collagen deposi tion.
Lymphocyte proliferative assay
Peripheral blood from healthy human donors was 
collected into heparinized containers (BD Biosciences), 
and peripheral blood mononuclear cells (PBMCs) were 
isolated by Ficoll‑Hypaque density gradient centrifu ga‑
tion. Responder human PBMCs were resuspended in 
RPMI 1640 medium containing 10% FBS, 2  mmol/L 
glutamine, 100  U/ml penicillin, and 100  µg/ml strepto‑
mycin, 0.1 mmol/L nonessential amino acids, 1 mmol/L 
sodium pyruvate, 20  mmol/L HEPES, and 50 μmol/L 
2‑mercaptoethanol (Invitrogen). PBMCs were seeded in 
triplicates at 1 × 105 cells/100 µl per well in 96‑well round‑
bottom plates (BD Biosciences). PHA was used at 5 μg/ml 
as a positive control mitogen to induce T‑cell proliferation. 
MPCs (5 × 104 cells) were added to obtain a final volume of 
300 µl. After 3 days of incubation, 1  µCi/well [3H]‑
thymidine (GE Healthcare) was added, and radioactivity 
incorporation over a 12‑hour period was determined by 
liquid scintillation counting. All experi ments were 
performed in triplicate and repeated at least twice.
Immunohistochemistry
Chondrogenic cell pellets were fixed in 4% buffered 
paraformaldehyde, rinsed with PBS, serially dehydrated, 
paraffin embedded, and sectioned at 10‑μm thickness. 
Sections were digested with 1 mg/ml hyaluronidase 
(Sigma) or 20 μg/ml proteinase K (Roche Diagnostics) in 
10 mmol/L Tris‑HCl (pH 7.5) for 30 minutes at 37°C. The 
sections were then incubated overnight at room 
temperature with the following antibodies in Tris‑
buffered saline containing 0.1% bovine serum albumin: 
antibodies to aggrecan and collagen type II (Develop‑
mental Studies Hybridoma Bank), and antibodies to 
fibronectin (R&D). Immunostaining was detected by 
using the chromogenic streptavidin‑peroxidase Histo‑
stain SP Kit for DAB (Zymed Laboratories, San Francisco, 
CA), and imaged by using an inverted microscope 
equipped with a color charge‑coupled device camera.
RNA isolation and real-time reverse transcription-
polymerase chain reaction (RT-PCR)
RNA was extracted from monolayer cultures of BM‑
MPCs, T‑MPCs, DP‑MPCs and, M‑MPCs by using the 
RNeasy Kit (Qiagen). Total RNA (1 μg) was reverse 
transcribed by using the Multiscribe reverse 
transcriptase (Applied Biosystems). Real‑time PCR 
reactions were performed as previously described [42]. 
Gene‑specific primers (forward and reverse) were 
designed based on GenBank cDNA sequences (primer 
sequences available on request). Specific transcript 
levels were normalized by comparison with the house‑
keeping gene, glyceraldehyde‑3‑phosphate dehydro ge‑
nase (GAPDH).
Western blot
MPCs cultures were treated with activin A (10 ng/ml) 
for 48 hours, and homogenized in RIPA lysis buffer 
(Sigma) supplemented with protease and phosphatase 
inhibitors. Extracted proteins were separated on 12% 
polyacrylamide gels and electroblotted. The blots were 
immunoprobed for GAPDH and Sox‑2 (Santa Cruz, 
CA). Appropriate horseradish peroxidase–conjugated 
secondary antibodies were used for detection.
Activin A quantification
Activin A in culture supernatants was quantified by 
using a commercially available enzyme‑linked immuno‑
sorbent assay kit (R&D Systems) according to the 
manufacturer’s protocol.
siRNA transfection
Small interfering RNA (siRNA) duplexes designed 
against human inhibin, beta A (activin A, activin AB 
alpha polypeptide), and the negative control siRNA 
obtained from Ambion (Applied Biosystems/Ambion, 
Austin, TX) were reconstituted by following the 
manufacturer’s guidelines. siRNAs were transfected into 
BM‑MPCs by electroporation with a total of 750,000 
cells in 300 µl of siPORT electroporation buffer 
containing 45 µl of 22.5 µg siRNA by using the BTX 
ECM 830 Electro Square Porator System (Harvard 
Apparatus). In brief, the mixture was transferred to a 
2‑mm gap BTX electroporation cuvette, which was then 
placed in the apparatus and exposed to two identical 
square‑wave pulses (parameters: 1,075 V, 105‑µs pulse 
length, 5‑second duration between pulses). After 
electroporation, the cuvettes were incubated for 
15  minutes at 37°C in a 5% CO2/95% air atmosphere. 
The transfected MPCs were then maintained for 
24  hours in culture medium under 5% CO2 at 37°C 
before differen tiation analyses.
Statistics
Data from the proliferation, RT‑PCR, and ELISA 
experiments were analyzed statistically by using 
Student’s t test, with statistical significance set at 
P < 0.05.
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Results
Differential cell properties among mesenchymal 
progenitor cells from various tissue sources
Before examining the role of activin A, the four types of 
MPCs (BM, T, DP, and M) were first examined in terms 
of several key properties.
Cell surface-marker expression
To confirm that these MPCs express typical cell‑surface 
markers, we performed fluorescence activated cell sort‑
ing (FACS) analysis. It was revealed that all MPCs were 
negative for CD14, CD34, and CD45 expression and 
positive for CD73, CD90, and CD105 (Table 1).
T-MPCs have a higher proliferation rate than other MPCs
Analysis of cell density as a function of culture time (48, 
96, 144, or 240 hours) in growth medium revealed that 
among the four different MPC populations tested, 
T‑MPCs proliferated at a significantly higher rate than 
did MPCs derived from the other tissues (Figure 1c).
BM-MPCs display the strongest chondrogenic and adipogenic 
potency, whereas DP-MCPs exhibit the highest level of matrix 
mineralization
We compared the differentiation potential of MPCs 
derived from bone marrow, tonsil, muscle, and dental 
pulp with the chondrogenic, osteogenic, and adipogenic 
lineages. Cultures of MPCs derived from the four tissues 
under chondrogenic conditions produced pellets with a 
similar morphology and a shiny surface that is charac‑
teristic of cartilaginous pellets. At day 21 of chondro‑
genesis, alcian blue (AB) and picrosirius histologic 
staining of the chondrogenic pellets derived from BM‑
MPCs, M‑MPCs, and DP‑MPCs all revealed the presence 
of a sulfated proteoglycan‑ and collagen‑rich extracellular 
matrix. In comparison, in T‑MPC pellets, the matrix 
contained considerably less sulfated proteoglycans, 
where as collagen staining was highly positive (Figure 2a). 
Immunohistochemistry showed that all MPC pellets 
produced collagen type II (COL2) and aggrecan (AGN), 
although the staining intensities for both COL2 and AGN 
were higher in BM‑MPCs compared with those of 
T‑MPCs, M‑MPCs, and DP‑MPCs (Figure 2a). Quanti tative 
RT‑PCR analysis of day 21 cultures showed that, in response 
to the chondrogenic culture conditions and induction 
medium, expression of COL2 was upregulated in all 
cultures, with the highest level in BM‑MPCs (Figure 2d).
Although to a lesser extent for T‑MPCs, MPCs from 
the four tissue sources cultured for 21 days in osteogenic 
medium exhibited increased ALP activity and produced a 
mineralized matrix that stained positive with alizarin red, 
with the highest level of mineralization seen in DP‑MPCs 
cultures (Figure 2b). Under the same osteogenic condi‑
tions, gene expression of osteocalcin (OC), associated 
with mature osteoblasts, was significantly increased 
compared with the undifferentiated cells at day zero (D0) 
(Figure 2e).
MPCs cultured in adipogenic medium formed charac‑
teristic intracellular lipid‑rich vacuoles that stained 
positive with oil red O. Compared with BM‑MPCs, T‑
MPCs, and M‑MPCs, DP‑MPCs displayed a lesser ability 
to form lipid vacuoles (Figure 2c). MPCs derived from 
the different tissue sources under adipogenic induction 
also upregulated the expression of peroxisome 
proliferator‑activated receptor‑γ (PPAR‑γ), a master 
regulator of adipogenesis, as well as lipoprotein lipase 
(LPL) (Figure 2f ). To summarize, the nonequivalence in 
differentiation potency of the MPCs included (a) BM‑
MPCs displayed a significantly greater chondrogenic 
potential; (b) DP‑MPCs presented a higher capacity for 
extracellular matrix mineralization; and (c) T‑MPCs 
showed an inferior ability to differentiate into chondro‑
cytes and osteoblasts but a high adipogenic potential.
BM-MPCs exhibit greater immunosuppressive properties
In addition to their multilineage differentiation potential, 
MPCs have been shown to display immunoregulatory 
properties that have prompted consideration of their use 
in bone marrow transplantation [3,43,44]. Although the 
exact immunosuppressive mechanisms of MPCs are 
unknown, the capacity of MPCs to suppress T‑cell proli‑
fera tion stimulated by allogeneic lymphocytes, dendritic 
cells, and phytohemagglutinin (PHA) is well documented 
[45,46]. The immunosuppressive properties of the MPCs 
derived from different tissue sources were tested in a 
lymphocyte proliferative assay by using human peripheral 
blood mononuclear cells (PBMCs) from healthy donors 
and stimulated with PHA, a mitogen. The addition of BM‑
MPCs, T‑MPCs, M‑MPCs, and DP‑MPCs to the activated 
PBMCs inhibited the PHA‑induced prolifera tive response 
of PBMCs (Figure 1d). The immuno modulatory activity of 
Table 1. Surface epitope phenotype of bone marrow-, 
tonsil-, muscle-, and dental pulp-derived mesenchymal 
progenitor cells*
 BM-MPCs T-MPCs M-MPCs  DP-MPCs
CD14 – _ _  _
CD34 _ _ _  _
CD45 _ _ _  _
CD73 + + +  +
CD90 + + +  +
CD105 + + +  +
*Surface epitopes or CD markers identified on the basis of immuoreactivity 
analyzed by fluorescence-activated cell sorting (FACS). FACS analysis showed 
that more than 95% of these cells were negative (-) for the expression of CD14, 
CD34, and CD45, and were positive (+) for CD73, CD90 and, CD105. Controls 
consisted of fluorescence observed with isotypic controls. BM, bone marrow; DP, 
dental pulp; M, muscle; MPC, mesenchymal progenitor cell; T, tonsil.
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BM‑MPCs was significantly more pronounced than that 
of T‑MPCs, M‑MPCs, or DP‑MPCs (Figure 1d).
Involvement of activin A in the regulation of mesenchymal 
progenitor cell properties
Given that the MPCs from the various tissue sources 
exhibit differences in terms of cell proliferation, multi‑
potency, and immunomodulatory properties, we next 
examined the involvement of activin A by analyzing 
whether activin A (a) is expressed differentially in these 
MPC populations, (b) regulates MPC differentiation 
potential, and (c) regulates Sox2 expression in the MPCs.
Activin A distinguishes mesenchymal progenitor cells from 
different tissue sources
ELISA was used to quantify activin A secretion in the 
supernatants of MPCs derived from the four tissue 
sources. M‑MPCs and BM‑MPCs expressed the highest 
levels of activin A, whereas T‑MPCs had the lowest level 
(Figure 1a). Next, the activin A:FS ratio was determined, 
because activin A bioactivity is also regulated by FS. 
Quantitative RT‑PCR results showed that the activin 
A:FS level was also significantly lower in T‑MPCs than in 
the other MPCs tested (Figure 1b).
Activin A expression levels regulate mesenchymal progenitor-
cell differentiation potential
Because BM‑MPCs exhibited high activin A expression 
level as well as the highest chondrogenic potential among 
the MPCs tested, we next determined the role of activin A 
in their multipotency by silencing of activin A in 
BM‑MPCs. With the transfection protocol using 22.5 µg 
of Cy3‑conjugated control siRNA, a transfection effici‑
ency of 91.66 ± 1.36% at day 2 and of 57.36 ± 3.27% at day 
7 was achieved. BM‑MPCs were transfected with either 
activin A or control siRNA oligonucleotides. Analysis of 
culture supernatants demonstrated that activin A siRNA 
transfection significantly reduced activin A level 
(0.81  ±  0.08 ng/ml) compared with the si Control 
(2.32  ±  1.12 ng/ml) (Figure 3a). Twenty‑four hours after 
transfection with gene‑specific designed siRNA against 
activin A or with the Control siRNA, BM‑MPCs were 
Figure 1. Activin A expression profile, proliferative rate, and immunosuppressive characteristics of MPCs from different tissue sources. 
(a) ELISA quantification of secreted activin A. Results are expressed as the mean of secretion in 48-hour supernatants of three cell cultures (mean 
± S.D.). (b) Activin A:follistatin ratio by real-time RT-PCR. (c) Cell-proliferation rate determined by using CCK-8. BM-MPCs, T-MPCs, M-MPCs, and 
DP-MPCs were plated in 96-well plates at 1 × 104 cells per well and cultured in growth medium for 48, 96, 144, and 240 hours. (d) Proliferative 
activity of T cells stimulated with PHA. Responding PBMCs were stimulated with PHA at 5 µg/ml in the presence or absence of 5 × 104 MPCs. The 
proliferative response of T cells is represented as a percentage of PHA control (mean ± SD of triplicates). *P ≤ 0.05, versus BM-MPCs; **P ≤ 0.05 
versus PHA.
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induced to differentiate toward the chondrogenic, osteo‑
blastic and adipocytic lineages. On activin A knockdown, 
BM‑MPCs displayed decreased chondro genic and 
osteo genic potentials. By day 21, BM‑MPCs transduced 
with activin A siRNA, and induced to differentiate into 
chondrocytes, formed a pellet similar to the un transfected 
Figure 2. In vitro-induced differentiation of MPCs from different tissue sources. (a-d) Chondrogenic differentiation evaluated after 21 days 
in micropellet culture. (a) Immunohistochemical analysis of cartilage markers (COL2 and AGN) and alcian blue (AB) and picrosirius (PS) staining in 
pellet cultures of MPCs. (d) Expression of COL2, a specific marker for chondrogenesis, measured in differentiated MPC cultures compared with day 0 
(D0) cultures, determined by quantitative RT-PCR with GAPDH as an internal control. (b-e) Osteogenic differentiation of MPCs assessed after 21-day 
culture in osteogenic medium. (b) All MPCs tested exhibited ALP activity and produced a mineralized matrix stained with alizarin red. T-MPCs 
displayed less alizarin red staining compared with BM-MPCs, M-MPCs, and DP-MPCs. (e) Significant upregulation of the expression of osteocalcin 
(OC), an osteoblast-specific gene, compared with undifferentiated MPCs was observed after osteogenic induction of BM-MPCs, T-MPCs, M-MPCs, 
and DP-MPCs compared with D0 cultures. (c-f) Adipogenic differentiation of MPCs cultured in adipogenic medium for 21 days. (c) All MPCs tested 
exhibited lipid-containing intracellular vacuoles that stained with oil red O at the end of the differentiation period. (f) MPCs cultured in adipogenic 
medium upregulated the expression of adipocyte-specific genes (PPAR-γ and LPL) compared with MPCs at D0. Quantitative RT-PCR data represent 
the mean ± SD in three independent experiments. *P ≤ 0.05, versus D0; **P ≤ 0.05, versus BM-MPCs.
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cells but with a reduced production of COL2 and AGN. 
Histologic staining showed a clear decrease in sulfated 
proteoglycan content and in fibrous collagen matrix, as 
assessed by alcian blue and Picrosirius red staining, 
respectively (Figure 3b). This observation was supported 
by the decrease in COL2 mRNA expres sion in pellets 
formed with activin A siRNA transfected cells, as assessed 
by quantitative RT‑PCR (Figure 3c). BM‑MPCs lacking 
activin A and induced to undergo osteogenesis also 
displayed decreased mRNA‑expression levels of 
osteoblastic markers such as OC and ALP (Figure 3c).
Activin A knockdown also affected matrix mineraliza‑
tion in osteogenically induced BM‑MPCs compared with 
the untransfected cells (Figure 3b). Additionally, trans‑
fection of BM‑MPCs with activin A siRNA enhanced 
their differentiation toward the adipocytic lineage. 
Compared with BM‑MPCs transfected with the Control 
siRNA, activin A knockdown in BM‑MPCs significantly 
increased the expression level of PPAR‑γ and LPL 
(0.01  ±  0.007 to 0.03 ± 0.01 and 0.004 ± 0.001 to 
0.08  ±  0.08, respectively) (Figure 3c). In summary, the 
transient knockdown of activin A in BM‑MPCs at the 
Figure 3. Role of activin A in MPC multipotency. BM-MPCs transiently transfected either with control siRNA or with activin A siRNA were 
analyzed. (a) Activin A secretion level in the supernatant of transfected BM-MPCs quantified by ELISA 3 days (D3) after transfection showed 
the efficiency of knockdown by using activin A siRNA. (b, c) Effect of activin A knockdown on BM-MPC and T-MPC chondrogenic potential. 
Chondrogenic differentiation was evaluated after 21 days in micropellet culture. (b) Immunohistochemical analysis of cartilage markers (COL2 
and AGN) in pellet cultures of BM-MPCs and T-MPCs as well as alcian blue (AB) and picrosirius red (PS) staining revealed that, compared with the 
untransfected and Control siRNA, MPCs transfected with activin A siRNA exhibited less chondrogenic potential. (c) Quantitative RT-PCR also showed 
decreased expression of COL2 in MPCs transfected with activin A siRNA, compared with the cells transfected with control siRNA (c). (b, c) Effect 
of activin A knockdown on BM-MPC osteogenic potential. Both the expression levels of the osteogenic markers (OC and ALP), determined by 
quantitative RT-PCR, and alizarin red staining, revealed a decrease in the osteogenic activity of BM-MPCs with activin A knockdown. (b, c) Effect 
of activin A knockdown on BM-MPC adipogenic potential. Both expression levels of the adipogenic markers (PPAR-γ and LPL), determined by 
quantitative RT-PCR and oil red O staining, revealed an increase in the adipogenic potential of BM-MPCs with activin A knockdown, compared with 
BM-MPCs transfected with the irrelevant Control siRNA. RT-PCR data represent the mean ± SD of three independent experiments. *P ≤ 0.05, versus 
Control siRNA.
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early stages of the differentiation process appeared to 
stimulate adipogenesis while inhibiting chondrogenesis 
and osteogenesis.
Activin A increases Sox2 expression in BM-mesenchymal 
progenitor cells
Sox2, a transcription factor highly expressed in undiffer‑
entiated ES cells, has been shown to stabilize ES cells in a 
pluripotent state [47,48]. With Western blot analysis, we 
observed that although untreated MPCs expressed 
undetectable or low levels of Sox2 protein, its level 
increased 48 hours after the treatment with 10 ng/ml of 
activin A (Figure 4a).
The activin A:follistatin ratio was assessed by using 
quantitative RT‑PCR before and after the differentiation 
of BM‑MPCs into chondrocytes, osteoblasts, and 
adipocytes. The activin A:follistatin ratio was significantly 
lower in all differentiated cells compared with 
undifferentiated BM‑MPCs (Figure 4b). In a similar 
manner, the Sox2 mRNA expression level was also 
significantly decreased in the differentiated cells 
compared with undifferentiated BM‑MPCs (Figure 4c).
Discussion
To realize the potential of MPCs in clinical applications, 
it is important to understand the biologic regulation of 
their multipotency. We attempted to gain insights into 
this by analyzing comparable MPCs derived from various 
tissue sources that have similar but non‑identical 
characteristics and biologic activities, and we observed a 
requirement for activin A expression in the maintenance 
of MPC identity, as well as the regulation of MPC func‑
tions. Moreover, our findings strongly suggest the high 
potency of bone marrow‑derived MPCs compared with 
MPCs from other tissue sources.
We showed that MPCs isolated from bone marrow, 
tonsil, muscle, and dental pulp all display phenotypic and 
functional properties that currently characterize MPCs. 
However, significant differences in activin A expression 
levels and, more important, in the activin A:follistatin 
ratios, which corroborate with MPC multipotency and 
immunosuppressive properties, were observed. Activins 
bind to the activin type IIA or type IIB receptors, leading 
to recruitment and phosphorylation of the activin type IB 
receptor, which in turn phosphorylates intracellular 
Figure 4. Relation between Sox2 expression levels and activin A:follistatin expression ratio in MPCs from different tissue sources. 
(a) Western blot analysis of Sox2 expression in BM-MPCs, T-MPCs, M-MPCs, and DP-MPCs before and after a 48-hour treatment with 10 ng/ml of 
activin A. (b) Activin A:follistatin expression ratio determined by quantitative RT-PCR in BM-MPCs before (day 0 (0)) and after their differentiation 
along chondrogenic, osteogenic, and adipogenic lineages. (c) mRNA expression levels of Sox2 in undifferentiated (day 0 (0)) and chondro-, osteo- 
and adipo-differentiated BM-MPCs. The values at day 0 (0) corresponding to the mRNA ratio of activin A:follistatin (b) to the mRNA level of Sox2 (c) 
relative to GAPDH were assigned the values of 100% ± SD. *P ≤ 0.05, versus Day 0.
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signaling proteins, Smad2 or Smad3. Activin A signaling 
is inhibited by extracellular action of follistatin, a soluble 
protein that functions as an activin‑binding protein to 
prevent activin from interacting with its receptor. Activin 
A but not the activin A:follistatin ratio was significantly 
higher in M‑MPCs compared with the other MPCs 
tested. In T‑MPCs, both activin A level and activin 
A:follistatin ratio were significantly lower compared with 
the other MPCs. In parallel, we showed that the prolifera‑
tive rate of T‑MPCs was significantly higher compared 
with the other MPCs studied. This observation suggests 
that the endogenous high level of activin A might reduce 
the proliferation of BM‑MPCs, M‑MPCs, and DP‑MPCs 
compared with that of T‑MPCs. Although activin A is 
widely expressed by various cells, the effects of activin A 
are diverse, and cell type dependent. In general, activin A 
exerts antiproliferative effects on many cell types, 
including epithelial cells and vascular endothelial cells 
and lymphocytes [49,50]. However, several cell types, 
including fibroblast‑like synoviocytes (FLS) and lung 
fibro blasts, proliferate in response to activin A [51,52]. In 
the study using FLS, the authors emphasized the 
differences between the amount of activin A produced by 
the FLS (<1 ng/ml) and the amount of exogenous activin 
A necessary to promote FLS proliferation (250 ng/ml).
Besides cell growth, activin A has been widely studied 
for its role in cell differentiation. Several studies demon‑
strated a role for activins in bone metabolism. During 
differentiation and bone formation, osteoblasts produce a 
characteristic extracellular matrix that eventually under‑
goes mineralization. Although activin A has been 
described to promote osteoblastogenesis in murine bone 
marrow cultures and to enhance in vivo bone formation 
and fracture healing in rodents [27‑29,32], other reports 
described an inhibitory effect of activin on osteoblast 
differentiation in rat and murine osteoblasts [30,31]. 
These opposite effects of activin A in murine rodent 
models might be explained by the cell type used (that is, 
activin A is a potent regulator of osteogenesis with a 
positive effect on uncommitted progenitor cells and an 
inhibitory action on mature osteoblasts). This postulate is 
supported by the finding that activin A signaling in 
osteoblasts is tightly controlled in a differentiation‑
dependent manner [53]. Mineralizing osteoblast cultures 
showed decreased activin A production. Activin A 
signaling controls human osteoblast differentiation and 
function and inhibits matrix mineralization through 
mechanisms that include altered extracellular matrix 
composition and maturation. The expression of activin A 
in bone, taken together with its effect on mineralization 
in vitro, strongly suggests a biologically important role 
for activin A in human osteoblast differentiation and 
bone metabolism [53]. In this work, we observed that 
T‑MPCs, with lower level of activin A expression 
compared with the other MPCs, also exhibit lower 
osteogenic potential, as shown by ALP activity and 
alizarin red staining. The involvement of activin A in the 
early events of osteogenesis is also supported by the 
effects of siRNA‑mediated transient knockdown of 
activin A gene expression in BM‑MPCs induced to 
under go osteogenesis. Activin A knockdown reduced 
both the expression of osteoblast‑specific markers and 
matrix mineralization at day 21. In addition, we showed 
that in BM‑MPCs under osteogenic induction, the activin 
A:follistatin ratio was significantly decreased at the end 
of the differentiation period compared with day 0. An 
activin‑dominant microenvironment thus appears to be 
critical for the early stage of osteoblastic differentiation. 
Compared with BM‑MPCs, M‑MPCs, and DP‑MPCs, 
T‑MPCs with the lowest activin A level also exhibit the 
lowest chondrogenic potential. In addition, we observed 
that activin A knockdown in BM‑MPCs significantly 
affects their chondrogenic potential. The activin A 
expression level in MPCs thus appears to govern both 
their chondrogenic and osteogenic potential. Our study 
is consistent with previous studies showing that during 
skeletal development, activin A is involved early at the 
beginning of the cascade of events promoting mesen‑
chymal condensations and thus chondrogenic/osteogenic 
differentiation [54,55]. At the early phase of adipogenesis, 
activin A treatment suppresses differentiation, which 
could be rescued with follistatin [34]. This inhibitory 
effect of activin A on adipogenesis of progenitor cells acts 
through suppression of the adipocyte transcriptional 
factor cascade [33]. Our results show that activin A 
knockdown in BM‑MPCs undergoing adipogenic induc‑
tion results in a significant increase in their adipogenic 
activity. Taken together, these observations raise the 
possibility that the activin A expression level in MPCs is a 
key determinant in their commitment to a specific mesen‑
chymal lineage, and activin signaling and activin target 
genes might be crucial for controlling MPC multipotency.
Another functional characteristic of MPCs or mesen‑
chymal stem cells (MSCs) is their capacity to inhibit the 
proliferation of activated T cells [45]. The precise 
mechanisms underlying the immunosuppressive effect of 
MPCs/MSCs still remain to be clarified. The suppression 
of T‑cell proliferation stimulated by allogeneic lympho‑
cytes, dendritic cells, and mitogens, such as PHA or 
concanavalin A, has been well documented (for review, 
see [3]). Although controversial results have been reported, 
more convergent data now suggest that MPCs/MSCs may 
act by suppressing the differentiation of mono cytes into 
mature dendritic cells (DC) thus impairing the 
stimulation of T cells [46,56,57]. Interest ingly, in addition 
to its defined role in embryogenesis and erythroid cell 
differentiation in bone marrow, activin A has been shown 
to exert antiinflammatory effects [58,59]. Activin A was 
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suggested to play a functional role in the suppression of 
inflammatory or immune processes [60]. More recently, 
activin A has been described as a novel DC‑derived cyto‑
kine that potently attenuates CD40 ligand‑specific 
cytokine and chemokine production. Blocking autocrine 
activin‑A signaling in DCs by using its antagonist, 
follistatin, enhanced production of DC cytokines (IL‑6, 
IL‑10, IL‑12p70, and TNF‑α) [61]. These correlations 
between activin A and immunosuppression support our 
data showing that lower level of activin A produced by 
T‑MPCs, compared with other MPC types, corresponds 
to their significantly lower immunosuppressive potential. 
However, M‑MPCs and DP‑MPCs, with an activin 
A:follistatin ratio similar to that of BM‑MPCs, are also 
significantly less immunosuppressive than BM‑MPCs. 
This might be explained by the fact that whereas DC 
maturation inhibition is certainly a mechanism by which 
MPCs display suppressive activity, it probably is not the 
main mechanism.
In addition, in this report, we show that (a) MPCs 
express the embryonic transcription factor Sox2 at a very 
low level and that its expression is enhanced on treatment 
with 10 ng/ml of activin A; (b) M‑MPCs exhibit higher 
expression levels of both activin A and Sox2 compared 
with BM‑MPCs, T‑MPCs, and DP‑MPCs; and (c) the 
down regulation of the activin A:follistatin ratio in 
differentiated BM‑MPCs parallels a reduction in Sox2 
expression level. Recent findings with hESCs show that 
activin A induces the expression of Oct4, Nanog, Nodal, 
Wnt3, bFGF, and FGF8, and is necessary and sufficient 
for the maintenance of self‑renewal and pluripotency of 
hESCs [19]. In MSCs, Oct4 knockdown results in 
markedly decreased levels of Nanog and Sox2 expression 
[62]. Together, these studies strongly suggest that activin 
A is a key regulator in the maintenance of pluripotency of 
stem cells acting upstream of the master embryonic 
transcription factors Oct4, Nanog, and Sox2.
Conclusions
MPCs are defined by their ability to give rise to meso‑
dermal cell types. Multipotency in cultured MPCs 
derived from various tissues results from the integration 
of multiple signals to preserve this identity. In 
demonstrating a requirement of activin A, we have 
shown a novel candidate signaling mechanism for the 
maintenance of multipotency of MPCs.
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